-
11:05:36 PM

PFE Stock News

12/01/22 10:00 AM
NYSE : PFE
Pfizer Invites Public to Register for Webcast of Pfizer Near-Term Launches + High-Value Pipeline Day
Pfizer Inc. invites investors and the general public to access a live video webcast of its Near-Term Launches+ High-Value Pipeline Day on Monday, December 12, 2022 from 1:00 p.m. EST to 6:00 p.m. EST, with an approximately 30 minute break at the midpoint. Pfizer business executives and scientific leadership will provide updates on the company’ s potential...
RHEA-AI
neutral
11/30/22 7:01 PM
NYSE : PFE
ViiV Healthcare Unveils a New Global Study Revealing Three Quarters of People Believe There Are Still Negative Perceptions When It Comes to People Living With HIV
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced new data from a perceptions survey which unveils a widespread gap in public knowledge and understanding of HIV worldwide. The survey, conducted online by Opinium in 2022, collected insights from 8,000 adults across eight...
RHEA-AI
neutral
11/11/22 10:00 AM
NYSE : PFE
conferences
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a discussion with David Denton, Chief Financial Officer, Executive Vice President, at the Wolfe Research Healthcare Conference on Friday, November 18, 2022 at 8:45 a.m. EST. About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global...
RHEA-AI
neutral
11/04/22 6:47 AM
NYSE, Nasdaq : PFE, BNTX
clinical trialcovid-19
Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine
Pfizer Inc. and BioNTech SE today announced updated data from a Phase 2/ 3 clinical trial demonstrating a robust neutralizing immune response one-month after a 30- µg booster dose of the companies’ Omicron BA.4/BA. 5- adapted bivalent COVID-19 vaccine. “As we head into the holiday season, we hope these updated data will encourage people...
RHEA-AI
neutral
11/03/22 9:10 AM
NYSE : PFE
Pfizer’s Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma
Pfizer Inc. today announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of people with relapsed or refractory multiple myeloma. Elranatamab is a B-cell maturation antigen- CD3-targeted bispecific antibody. “The FDA’ s Breakthrough...
RHEA-AI
very positive
11/02/22 12:45 PM
NYSE : PFE
Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers
Hedi Ben Brahim, CEO, and Dr. The Phase II study is evaluating TG4001, an investigational therapeutic cancer vaccine, in combination with avelumab compared to avelumab alone in patients with HPV16-positive anogenital tumors without liver metastases, through a continuing collaboration with the alliance of Merck KGaA, Darmstadt, Germany, and Pfizer, which is...
RHEA-AI
neutral
11/01/22 6:30 AM
NYSE : PFE
clinical trial
Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate
Pfizer Inc. today announced positive top-line data from the Phase 3 clinical trial MATISSE investigating its bivalent RSV prefusion vaccine candidate, RSVpreF or PF-06928316, when administered to pregnant participants to help protect their infants from RSV disease after birth. The pre-planned, interim efficacy analysis conducted by an external and...
RHEA-AI
neutral
10/25/22 10:05 AM
NYSE : PFE
ViiV Healthcare presents positive proof-of-concept findings for N6LS, an investigational, broadly neutralising antibody (bNAb) offering a potential new approach for the treatment of HIV
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from its phase IIa proof-of-concept study of N6LS, a novel, investigational, broadly neutralising antibody that is being studied at two dosing levels– a high dose and ten-fold lower dose, in adults living with...
RHEA-AI
neutral